PharmaForce investing $145M in Ohio sterile injectables operations

CDMO PharmaForce, a unit of Japan's Daiichi Sankyo that makes sterile injectable drugs, is expanding its capacity at facilities in Ohio.

A U.S. unit of Japan’s Daiichi Sankyo that makes sterile injectable drugs is expanding its capacity at facilities inn Ohio, pledging to add nearly 80 jobs in the process.

CDMO PharmaForce will invest about $145 million to add 140,000 square feet to its New Albany, Ohio, manufacturing and warehouse operations, according to an announcement from development group Columbus 2020. It will also add about 1,800 square feet to a production facility in Hilliard, Ohio. Work is set to begin in the first quarter of 2018.

PharmaForce is a unit of Luitpold Pharmaceuticals, which also owns American Regent. Luitpold Pharmaceuticals, in turn, is a unit of Daiichi Sankyo.


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

The expansion comes as other contractors also are beefing up sterile injectable capacity. New Jersey-based Catalent recently agreed to pay $950 million to buy Cook Pharmica to get its extensive biologics manufacturing operation in Bloomington, Indiana.

AMRI has recently doubled its bulk API aseptic manufacturing capacity at a facility in Spain.